<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02078180</url>
  </required_header>
  <id_info>
    <org_study_id>HHSF223201310164C</org_study_id>
    <secondary_id>HUM00081894</secondary_id>
    <nct_id>NCT02078180</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Bupropion Hydrochloride Products With Different Release Patterns</brief_title>
  <official_title>Pharmacokinetic Study of Bupropion Hydrochloride Products With Different Release Patterns</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this project are to determine if the bioavailability and release pattern of
      bupropion HCl products differ and if the genotype of the metabolic enzymes affects the
      saturation of intestinal enzymes with different dose strengths within one product line.
      Findings from this project will help the FDA Center for Drug Evaluation and Research's (CDER)
      Office of Generic Drugs improve policy development and review practice in the future for
      similar products, e.g. extended release oral drug products being metabolized in the gut wall
      and having multiple strengths.

      Aim 1: To compare the pharmacokinetics of bupropion and its metabolites in plasma in healthy
      individuals when they ingest different strengths of bupropion (75-300 mg) with variable
      release profiles (IR vs XL vs SR) in GI tract.

      Working hypothesis: Variation in release rate and mechanism of bupropion formulations in
      gastrointestinal (GI) tract will impact metabolism and saturation of bupropion in GI tract,
      which will generate different concentration of bupropion and its metabolites in plasma.

      Aim 2: To investigate pharmacogenomics of CYP 2B6 that influences metabolism, saturation, and
      pharmacokinetics of bupropion

      Working hypothesis: The gain of function of CYP2B6 variants (allele *4 and *22) in patients
      will increase the metabolism of bupropion in the GI tract and liver, reduce both local
      concentration and plasma concentration of bupropion, and thus cause non-bioequivalence when
      bupropion is released earlier in GI tract
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparision of the Buproprion Area Under the Concentration Time Curve (AUC) From Time 0 to 96 Hours by Type of Formulation and Dosage</measure>
    <time_frame>4 days</time_frame>
    <description>Each formulation of buproprion has a different rate of release. Some release the drug immediately while others release the drug slowly. We will compare the exposure of buproprion by formulation and dose by looking at the area under the concentration time curve. The area under the concentration time curve is a mathematical way of looking at drug exposure in the body. The reported values are AUC (0-96 hours).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparision of the Buproprion Maximum Concentration (Cmax) by Type of Formulation and Dosage</measure>
    <time_frame>4 days</time_frame>
    <description>Each formulation of buproprion has a different rate of release. Some release the drug immediately while others release the drug slowly. We will compare the exposure of buproprion by formulation and dose by looking at the maximum concentration. The maximum concentration depends on the rate of drug release and so looking at this value can help us compare differences between formulation.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>generic bupropion IR75</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One oral dose of generic bupropion IR75</description>
  </arm_group>
  <arm_group>
    <arm_group_label>generic bupropion IR100</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One oral dose of generic bupropion IR100</description>
  </arm_group>
  <arm_group>
    <arm_group_label>generic bupropion SR100</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One oral dose of generic bupropion SR100</description>
  </arm_group>
  <arm_group>
    <arm_group_label>generic bupropion SR150</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One oral dose of generic bupropion SR150</description>
  </arm_group>
  <arm_group>
    <arm_group_label>generic bupropion XL150</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One oral dose of generic bupropion XL150</description>
  </arm_group>
  <arm_group>
    <arm_group_label>generic bupropion XL300</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One oral dose of generic bupropion XL300</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>generic bupropion</intervention_name>
    <description>We are comparing different formulations of bupropion that release this drug at different rates. The abbreviation IR75 means immediate release and the number is the dose in mg. The other abbreviations represent SR for sustained-release and XL for extended release, which release the drug slower than the IR formulation.</description>
    <arm_group_label>generic bupropion IR75</arm_group_label>
    <arm_group_label>generic bupropion IR100</arm_group_label>
    <arm_group_label>generic bupropion SR100</arm_group_label>
    <arm_group_label>generic bupropion SR150</arm_group_label>
    <arm_group_label>generic bupropion XL150</arm_group_label>
    <arm_group_label>generic bupropion XL300</arm_group_label>
    <other_name>Wellbutrin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers 25 to 55 years old.

          -  Volunteers have a Body Mass Index (BMI), calculated from the ratio of height and
             weight, within a range of 18.5 to 35.

          -  Willing to be medication and supplement free 2 weeks prior to beginning study, and
             throughout the study. All forms of birth control are okay.

        Exclusion Criteria:

          -  Individuals unwilling or unable to comply with the study protocol (e.g. unable to
             remain medication or supplement free during the study).

          -  Individuals unwilling or unable to take bupropion or have an allergy to bupropion

          -  Any medical or surgical conditions which might significantly alter bupropion
             absorption (e.g., history of malabsorption, liver disease, gastric bypass surgery )

          -  Individuals with a history of psychiatric or neurological illness, including seizure
             disorders

          -  Nicotine dependence

          -  Alcohol dependence

          -  Pregnant or nursing women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Duxin Sun, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-2700</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2014</study_first_submitted>
  <study_first_submitted_qc>March 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2014</study_first_posted>
  <results_first_submitted>July 11, 2017</results_first_submitted>
  <results_first_submitted_qc>September 1, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 6, 2017</results_first_posted>
  <last_update_submitted>September 1, 2017</last_update_submitted>
  <last_update_submitted_qc>September 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Duxin Sun</investigator_full_name>
    <investigator_title>Professor of Pharmaceutical Sciences</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>IR75, IR200, SR100, SR150, XL150, XL300</title>
          <description>Participants were randomized to receive one pill each of IR 75, IR 100, SR 100, SR 150, XL 150 and XL 300,in randomized order at six time points. Given the large number of possible sequence combinations, participants are reported as a single Participant Flow Arm with Milestones used to indicate how many participants received each intervention</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>IR75</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>IR100</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>SR100</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>SR150</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>XL 150</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>XL 300</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IR 75, IR 100, SR 100, SR 150, XL 150 and XL 300</title>
          <description>Participants were randomized to receive one pill each of IR 75, IR 100, SR 100, SR 150, XL 150 and XL 300,in randomized order at six time points. Given the large number of possible sequence combinations, participants are reported as a single Participant Flow Arm with Milestones used to indicate how many participants received each intervention</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt;25 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25-65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comparision of the Buproprion Area Under the Concentration Time Curve (AUC) From Time 0 to 96 Hours by Type of Formulation and Dosage</title>
        <description>Each formulation of buproprion has a different rate of release. Some release the drug immediately while others release the drug slowly. We will compare the exposure of buproprion by formulation and dose by looking at the area under the concentration time curve. The area under the concentration time curve is a mathematical way of looking at drug exposure in the body. The reported values are AUC (0-96 hours).</description>
        <time_frame>4 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Generic Bupropion IR75</title>
            <description>One oral dose of generic bupropion IR75
generic bupropion: We are comparing different formulations of bupropion that release this drug at different rates. The abbreviation IR75 means immediate release and the number is the dose in mg. The other abbreviations represent SR for sustained-release and XL for extended release, which release the drug slower than the IR formulation.</description>
          </group>
          <group group_id="O2">
            <title>Generic Bupropion IR100</title>
            <description>One oral dose of generic bupropion IR100
generic bupropion: We are comparing different formulations of bupropion that release this drug at different rates. The abbreviation IR75 means immediate release and the number is the dose in mg. The other abbreviations represent SR for sustained-release and XL for extended release, which release the drug slower than the IR formulation.</description>
          </group>
          <group group_id="O3">
            <title>Generic Bupropion SR100</title>
            <description>One oral dose of generic bupropion SR100
generic bupropion: We are comparing different formulations of bupropion that release this drug at different rates. The abbreviation IR75 means immediate release and the number is the dose in mg. The other abbreviations represent SR for sustained-release and XL for extended release, which release the drug slower than the IR formulation.</description>
          </group>
          <group group_id="O4">
            <title>Generic Bupropion SR150</title>
            <description>One oral dose of generic bupropion SR150
generic bupropion: We are comparing different formulations of bupropion that release this drug at different rates. The abbreviation IR75 means immediate release and the number is the dose in mg. The other abbreviations represent SR for sustained-release and XL for extended release, which release the drug slower than the IR formulation.</description>
          </group>
          <group group_id="O5">
            <title>Generic Bupropion XL150</title>
            <description>One oral dose of generic bupropion XL150
generic bupropion: We are comparing different formulations of bupropion that release this drug at different rates. The abbreviation IR75 means immediate release and the number is the dose in mg. The other abbreviations represent SR for sustained-release and XL for extended release, which release the drug slower than the IR formulation.</description>
          </group>
          <group group_id="O6">
            <title>Generic Bupropion XL300</title>
            <description>One oral dose of generic bupropion XL300
generic bupropion: We are comparing different formulations of bupropion that release this drug at different rates. The abbreviation IR75 means immediate release and the number is the dose in mg. The other abbreviations represent SR for sustained-release and XL for extended release, which release the drug slower than the IR formulation.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparision of the Buproprion Area Under the Concentration Time Curve (AUC) From Time 0 to 96 Hours by Type of Formulation and Dosage</title>
          <description>Each formulation of buproprion has a different rate of release. Some release the drug immediately while others release the drug slowly. We will compare the exposure of buproprion by formulation and dose by looking at the area under the concentration time curve. The area under the concentration time curve is a mathematical way of looking at drug exposure in the body. The reported values are AUC (0-96 hours).</description>
          <units>h*nanogram/milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="469" spread="177"/>
                    <measurement group_id="O2" value="667" spread="418"/>
                    <measurement group_id="O3" value="706" spread="304"/>
                    <measurement group_id="O4" value="1002" spread="516"/>
                    <measurement group_id="O5" value="740" spread="449"/>
                    <measurement group_id="O6" value="1356" spread="637"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparision of the Buproprion Maximum Concentration (Cmax) by Type of Formulation and Dosage</title>
        <description>Each formulation of buproprion has a different rate of release. Some release the drug immediately while others release the drug slowly. We will compare the exposure of buproprion by formulation and dose by looking at the maximum concentration. The maximum concentration depends on the rate of drug release and so looking at this value can help us compare differences between formulation.</description>
        <time_frame>4 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Generic Bupropion IR75</title>
            <description>One oral dose of generic bupropion IR75
generic bupropion: We are comparing different formulations of bupropion that release this drug at different rates. The abbreviation IR75 means immediate release and the number is the dose in mg. The other abbreviations represent SR for sustained-release and XL for extended release, which release the drug slower than the IR formulation.</description>
          </group>
          <group group_id="O2">
            <title>Generic Bupropion IR100</title>
            <description>One oral dose of generic bupropion IR100
generic bupropion: We are comparing different formulations of bupropion that release this drug at different rates. The abbreviation IR75 means immediate release and the number is the dose in mg. The other abbreviations represent SR for sustained-release and XL for extended release, which release the drug slower than the IR formulation.</description>
          </group>
          <group group_id="O3">
            <title>Generic Bupropion SR100</title>
            <description>One oral dose of generic bupropion SR100
generic bupropion: We are comparing different formulations of bupropion that release this drug at different rates. The abbreviation IR75 means immediate release and the number is the dose in mg. The other abbreviations represent SR for sustained-release and XL for extended release, which release the drug slower than the IR formulation.</description>
          </group>
          <group group_id="O4">
            <title>Generic Bupropion SR150</title>
            <description>One oral dose of generic bupropion SR150
generic bupropion: We are comparing different formulations of bupropion that release this drug at different rates. The abbreviation IR75 means immediate release and the number is the dose in mg. The other abbreviations represent SR for sustained-release and XL for extended release, which release the drug slower than the IR formulation.</description>
          </group>
          <group group_id="O5">
            <title>Generic Bupropion XL150</title>
            <description>One oral dose of generic bupropion XL150
generic bupropion: We are comparing different formulations of bupropion that release this drug at different rates. The abbreviation IR75 means immediate release and the number is the dose in mg. The other abbreviations represent SR for sustained-release and XL for extended release, which release the drug slower than the IR formulation.</description>
          </group>
          <group group_id="O6">
            <title>Generic Bupropion XL300</title>
            <description>One oral dose of generic bupropion XL300
generic bupropion: We are comparing different formulations of bupropion that release this drug at different rates. The abbreviation IR75 means immediate release and the number is the dose in mg. The other abbreviations represent SR for sustained-release and XL for extended release, which release the drug slower than the IR formulation.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparision of the Buproprion Maximum Concentration (Cmax) by Type of Formulation and Dosage</title>
          <description>Each formulation of buproprion has a different rate of release. Some release the drug immediately while others release the drug slowly. We will compare the exposure of buproprion by formulation and dose by looking at the maximum concentration. The maximum concentration depends on the rate of drug release and so looking at this value can help us compare differences between formulation.</description>
          <units>nanogram/milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" spread="36"/>
                    <measurement group_id="O2" value="136" spread="70"/>
                    <measurement group_id="O3" value="61" spread="29"/>
                    <measurement group_id="O4" value="78" spread="40"/>
                    <measurement group_id="O5" value="61" spread="34"/>
                    <measurement group_id="O6" value="111" spread="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Varied per person from 3 months to 10 months based on their randomization sequence and the time that it took to complete all phases of the study with washout between each formulation.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>IR 75, IR 100, SR 100, SR 150, XL 150 and XL 300</title>
          <description>Participants were randomized to receive one pill each of IR 75, IR 100, SR 100, SR 150, XL 150 and XL 300,in randomized order at six time points. Given the large number of possible sequence combinations, participants are reported as a single Participant Flow Arm with Milestones used to indicate how many participants received each intervention</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral vision loss</sub_title>
                <description>Briefly experienced loss of peripheral vision in right eye for approximately 30 minutes 6 days after dose. Full vision came back and participant did not experience anything out of the ordinary before or since resolution of vision loss.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Dizzyness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <description>Rash on both arms following completion of phase six of the study. Rash was located near site of blood draws on arms.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The small study sample size may have masked the contribution of pharmacogenetics to bupropion metabolism.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Duxin Sun</name_or_title>
      <organization>University of Michigan</organization>
      <phone>734-763-9783</phone>
      <email>pharmacy.research@umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

